* Oncorus Inc ONCR.OQ ONCR.O is expected to show no
change in
quarterly revenue when it reports results on March 8
(estimated).
* Refinitiv's mean analyst estimate for Oncorus Inc is for
a loss
of 69 cents per share. For the same quarter last year, the
company reported a loss of 56 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Oncorus Inc
is
$30, about 94.3% above its last closing price of $1.70.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.65 -0.64 -0.65 Missed -2.1
Jun. 30 2021 -0.57 -0.56 -0.60 Missed -6.5
Mar. 31 2021 -0.53 -0.53 -0.53 Met 0.9
Dec. 31 2020 -0.48 -0.48 -0.56 Missed -15.5
Sep. -0.94 -0.94 -21.73 Missed -2,211
30 2020 .7
This summary was machine generated March 4 at 13:43 GMT. All
figures in US dollars unless otherwise stated